Jaffer Ajani

Nov 14, 2024 | onclive.com | Jaffer Ajani

CommentaryPodcastNovember 14, 2024Author(s):Fact checked by:Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma. Welcome to OncLive On Air®! I’m your host today, Jax DiEugenio. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.

Oct 24, 2024 | ejso.com | Brian Badgwell |Neal Bhutiani |Y. Seo |Kristen Robinson |Michael White |Naruhiko Ikoma | +4 more

KeywordsHIPECgastric cancersurvivalGet full text accessLog in, subscribe or purchase for full access. References1. Ikoma, N. ∙ Chen, H.C. ∙ Wang, X. ... Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative TherapyAnnals of surgical oncology. Sep 2017; 24:2679-26872. Franko, J. ∙ Shi, Q. ∙ Meyers, J.P. ...

Jul 30, 2024 | nature.com | Sarina Piha-Paul |Vivek Subbiah |Aung Naing |Jaffer Ajani |Kanwal Raghav |Gordon Mills | +3 more

AbstractCancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2.

Oct 23, 2023 | bpno.dk | Jaffer Ajani

oktober 2023 In this MEDtalk, Professor of Gastrointestinal Oncology Jaffer A. Ajani, MD Anderson Cancer Center, USA, presents the most recent efficacy and safety findings from the phase III SPOTLIGHT study.